Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ikaria

- PMLiVE

Mallinckrodt files for bankruptcy protection in the US

Bankruptcy filing will reduce debts related to legal liabilities

- PMLiVE

US piles pressure on Mallinckrodt over alleged Acthar fraud

Drugmaker allegedly underpaid rebates owed to Medicaid

- PMLiVE

Mallinckrodt reaches tentative $1.6bn opioid settlement

Agreement reached with a plaintiff's executive committee

- PMLiVE

Mallinckrodt offloads CDMO for $250m

Move follows US opioid settlement

- PMLiVE

Humana lawsuit targets Mallinckrodt’s ‘billion-dollar golden goose’

Latest twist in long story of Acthar

- PMLiVE

Mallinckrodt doses first patient in muscular dystrophy trial

Repurposed drug could help delay decline in muscle function

- PMLiVE

Mallinckrodt pays $1.2bn for Sucampo Pharma

The Irish group will acquire Amitizia, Rescula and a pipeline of rare disease projects

- PMLiVE

Ireland’s Mallinckrodt buys US regenerative medicine firm

Stratatech’s StrataGraft in phase III testing for burns treatment

- PMLiVE

Ireland’s Mallinckrodt makes $1.3bn immunotherapy purchase

Will acquire Therakos to further boost its hospital drug portfolio

- PMLiVE

Mallinckrodt cuts $5.6bn deal to buy Questcor

Irish company continues move from medical imaging to pharma products

Mallinckrodt offers $1.3bn for Cadence Pharma

Deal would include injectable painkiller Ofirmev

FDA grants priority review to pain drug

Mallinckrodt’s MNK-795 is intended for the management of moderate to severe acute pain

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links